<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Frequently asked questions about CDKL5 gene therapy research, clinical trials, safety, and how to support this parent-led initiative.">
    <title>Frequently Asked Questions - CDKL5 Gene Therapy</title>
    <link rel="stylesheet" href="css/style.css">
    <link rel="stylesheet" href="css/colors.css">
    <style>
        /* Modern FAQ Layout - Option 1 */
        .faq-new-container {
            max-width: 900px;
            margin: 0 auto;
            padding: 3rem 1.5rem;
            background: var(--bg-page);  /* Warm cream */
        }
        
        /* Header */
        .faq-new-title {
            text-align: center;
            font-size: 2.5rem;
            color: var(--heading-primary);  /* Dark blue H1 */
            margin-bottom: 1rem;
            font-weight: 700;
        }
        .faq-new-subtitle {
            text-align: center;
            color: #666;
            font-size: 1.1rem;
            margin-bottom: 2.5rem;
        }
        
        /* Search Bar */
        .faq-search-new {
            position: relative;
            margin-bottom: 2rem;
        }
        .faq-search-new input {
            width: 100%;
            padding: 1rem 1rem 1rem 3rem;
            font-size: 1rem;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            transition: all 0.3s;
        }
        .faq-search-new input:focus {
            outline: none;
            border-color: #4f5bd5;
            box-shadow: 0 0 0 3px rgba(79, 91, 213, 0.1);
        }
        .faq-search-new::before {
            content: "üîç";
            position: absolute;
            left: 1rem;
            top: 50%;
            transform: translateY(-50%);
            font-size: 1.2rem;
        }
        
        /* Category Pills */
        .faq-categories {
            display: flex;
            gap: 0.75rem;
            flex-wrap: wrap;
            justify-content: center;
            margin-bottom: 2.5rem;
        }
        .faq-category-pill {
            padding: 0.6rem 1.2rem;
            border: 2px solid #e0e0e0;
            background: white;
            border-radius: 25px;
            cursor: pointer;
            font-weight: 600;
            font-size: 0.9rem;
            color: #666;
            transition: all 0.3s;
        }
        .faq-category-pill:hover {
            border-color: #ff6600;
            background: #fff3e0;
        }
        .faq-category-pill.active {
            background: linear-gradient(135deg, #ff6600 0%, #ff8c00 100%);
            color: white;
            border-color: #ff6600;
            box-shadow: 0 2px 8px rgba(255, 102, 0, 0.3);
        }
        
        /* Category Sections */
        .faq-section {
            margin-bottom: 2.5rem;
        }
        .faq-section.hidden {
            display: none;
        }
        .faq-section-title {
            font-size: 1.5rem;
            color: var(--heading-secondary);  /* Softer blue H2 */
            margin-bottom: 1rem;
            font-weight: 700;
            display: flex;
            align-items: center;
            gap: 0.5rem;
        }
        
        /* Accordion Items */
        .faq-accordion-item {
            margin-bottom: 0.75rem;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            overflow: hidden;
            transition: all 0.3s;
        }
        .faq-accordion-item:hover {
            border-color: #4f5bd5;
        }
        .faq-accordion-question {
            width: 100%;
            text-align: left;
            background: white;
            padding: 1.2rem 1.5rem;
            font-size: 1rem;
            font-weight: 600;
            color: var(--heading-secondary);  /* Softer blue */
            border: none;
            cursor: pointer;
            display: flex;
            justify-content: space-between;
            align-items: center;
            transition: background 0.3s;
        }
        .faq-accordion-question:hover {
            background: var(--section-warm);  /* Soft peach on hover */
        }
        .faq-accordion-question.active {
            background: #f0f0f0;
        }
        .faq-accordion-arrow {
            font-size: 1.2rem;
            transition: transform 0.3s;
            color: var(--primary-blue-light);
        }
        .faq-accordion-question.active .faq-accordion-arrow {
            transform: rotate(180deg);
        }
        .faq-accordion-answer {
            padding: 0 1.5rem;
            max-height: 0;
            overflow: hidden;
            transition: all 0.3s;
            background: var(--section-cool);  /* Soft blue background */
        }
        .faq-accordion-answer.active {
            padding: 1.2rem 1.5rem;
            max-height: 500px;
        }
        .faq-accordion-answer p {
            margin: 0;
            color: #555;
            line-height: 1.7;
            font-size: 0.95rem;
        }
        
        /* No Results */
        .faq-no-results {
            text-align: center;
            padding: 3rem;
            color: #999;
        }
        .faq-no-results.hidden {
            display: none;
        }
        
        /* Contact CTA */
        .faq-contact-cta {
            text-align: center;
            margin-top: 3rem;
            padding: 2rem;
            background: linear-gradient(135deg, #f7f6fd 0%, #e8eaf6 100%);
            border-radius: 12px;
        }
        .faq-contact-cta h3 {
            color: #303f9f;
            font-size: 1.3rem;
            margin-bottom: 0.5rem;
        }
        .faq-contact-cta p {
            color: #666;
            margin-bottom: 1rem;
        }
        .faq-contact-cta a {
            display: inline-block;
            background: linear-gradient(135deg, #ff6600 0%, #ff8c00 100%);
            color: white;
            padding: 0.8rem 2rem;
            border-radius: 25px;
            text-decoration: none;
            font-weight: 600;
            transition: transform 0.3s, box-shadow 0.3s;
            box-shadow: 0 4px 16px rgba(255, 102, 0, 0.3);
        }
        .faq-contact-cta a:hover {
            transform: translateY(-2px);
            box-shadow: 0 6px 20px rgba(255, 102, 0, 0.4);
        }
        
        /* Mobile Responsive */
        @media (max-width: 768px) {
            .faq-new-title {
                font-size: 2rem;
            }
            .faq-category-pill {
                font-size: 0.85rem;
                padding: 0.5rem 1rem;
            }
            .faq-section-title {
                font-size: 1.3rem;
            }
        }
    </style>
</head>
<body>
    <div data-include="inc/header.html"></div>
    
    <main class="faq-new-container">
        <!-- Header -->
        <h1 class="faq-new-title">Frequently Asked Questions</h1>
        <p class="faq-new-subtitle">Find answers to common questions about CDKL5 gene therapy</p>
        
        <!-- Search Bar -->
        <div class="faq-search-new">
            <input type="text" id="faqSearch" placeholder="Search FAQs...">
        </div>
        
        <!-- Category Pills -->
        <div class="faq-categories">
            <button class="faq-category-pill active" data-category="all">All</button>
            <button class="faq-category-pill" data-category="general">üß¨ General</button>
            <button class="faq-category-pill" data-category="participation">üíâ Participation</button>
            <button class="faq-category-pill" data-category="donations">üí∞ Donations</button>
            <button class="faq-category-pill" data-category="webinars">üì∫ Webinars</button>
            <button class="faq-category-pill" data-category="medical">üî¨ Medical</button>
            <button class="faq-category-pill" data-category="other">üìã Other</button>
        </div>
        
        <!-- FAQ Sections -->
        <div id="faqContent">
            <!-- General -->
            <div class="faq-section" data-category="general">
                <h2 class="faq-section-title">üß¨ General</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Is gene therapy designed for a specific child/mutation?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>No, the gene replacement therapy is designed to deliver a functional copy of the CDKL5 gene to restore protein expression, making it suitable for most loss-of-function mutations rather than being mutation-specific. It aims to address the underlying deficiency broadly across patients.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>How confident are you about the success of your CDKL5 gene therapy trial from 0 to 10?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Based on preclinical data showing phenotypic rescue in mouse models and positive FDA feedback, confidence is around 7-8, reflecting optimism from safety profiles and efficacy in animals, though human trials introduce uncertainties.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>What is your best guess about when there might be approval for the first trial?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>IND approval estimated mid-2026, with first-in-human dosing potentially starting late 2026, though timelines depend on toxicology results and FDA review.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>How much money is required for the project to get to trials?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Approximately $3.5 million is needed to advance to first-in-human trials, covering toxicology, manufacturing, and IND submission.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>How will this move forward in terms of funding?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Funding relies on donations and grants to reach $3.5M for trials; current efforts include community fundraising and potential pharma collaborations. Please donate via CDKL5GeneTherapy.com and share with others.</p>
                    </div>
                </div>
            </div>
            
            <!-- Participation & Eligibility -->
            <div class="faq-section" data-category="participation">
                <h2 class="faq-section-title">üíâ Participation & Eligibility</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>How can I know if I'm fit for the program?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Eligibility will be based on confirmed CDKL5 mutation, age, health status, and trial criteria (e.g., no contraindications to AAV9); more information for screening will be made available once IND is approved.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>If we are from another country, can we still participate?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes, international participation is possible, with trials planned in the US and India; visa and travel support may be available, subject to regulatory approvals.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Is there an optimal age to receive gene therapy?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Preclinical data suggest earlier intervention (neonatal or early childhood) maximizes benefits due to brain development stages, but studies show potential rescue even in older models (equivalent to adulthood), so no strict cutoff, though younger ages may yield better outcomes.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Is there a possibility for less than 6-year-olds to participate in gene therapy?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes, but more details will be available shortly based on inclusion/exclusion criteria after the IND.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>How do we put our children under consideration for upcoming gene trials?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Contact trial sites (e.g., UCSF, Boston Children's) for pre-screening; once trials start, eligibility will be assessed based on inclusion criteria.</p>
                    </div>
                </div>
            </div>
            
            <!-- Donations & Support -->
            <div class="faq-section" data-category="donations">
                <h2 class="faq-section-title">üí∞ Donations & Support</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>What organization is best to donate to for fastest progress?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>The CDKL5 Gene Therapy Coalition (via cdkl5genetherapy.com) for direct support of this AAV9 program, as it focuses specifically on advancing this gene therapy initiative.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Where can we provide a donation for this research?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Directly through cdkl5genetherapy.com.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>What do we do to help? Where do we donate?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Donate via cdkl5genetherapy.com; help by spreading awareness, participating in registries, or volunteering for advocacy to accelerate progress.</p>
                    </div>
                </div>
            </div>
            
            <!-- Webinars & Registry -->
            <div class="faq-section" data-category="webinars">
                <h2 class="faq-section-title">üì∫ Webinars & Registry</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Will we have access to the informative slide show from today?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes, the webinar is posted on the CDKL5genetherapy.com website under past webinars section.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Is there any registry for registering clinical trials?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes, patients can register on www.cdkl5genetherapy.com, which helps with eligibility screening and data collection for CDKL5 studies.</p>
                    </div>
                </div>
            </div>
            
            <!-- Medical & Scientific -->
            <div class="faq-section" data-category="medical">
                <h2 class="faq-section-title">üî¨ Medical & Scientific</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>CDKL5 helps in development of synapses. When gene therapy works, how will this rectify issues?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>The therapy restores CDKL5 protein to promote synaptic maturation and neuronal connectivity; in preclinical models, it rectifies stunted growth even post-development by enhancing microtubule dynamics. Reinforcement may involve therapies like physical/occupational to maximize gains, similar to other neurodevelopmental treatments.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Do we have access to data on how effective gene therapy has been for Rett Syndrome?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes, Rett Syndrome gene therapy trials (e.g., Taysha's TSHA-102, Neurogene's NGN-401) show improvements in motor function, seizures, and behavior in early data; details available on ClinicalTrials.gov or RSRT.org, with some patients gaining skills like hand use.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Why are pig models valuable for biodistribution and toxicology studies, and how do they compare to primate models?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Pigs provide a crucial bridge between small-animal studies and humans. A pig's brain is much larger than a rodent's and is closer to the size of a young child's brain. It has similar folds (gyri) and a comparable mix of white and gray matter as humans. Pigs also have cerebrospinal fluid (CSF) volumes and blood‚Äìbrain barrier properties that match humans when scaled for body size. These features let us test how our gene therapy distributes in a brain and body that behave more like those of a patient especially for route-of-administration, dosing-volume, and CSF dynamics assessments. We can even use clinical imaging (like MRI) and collect fluid or tissue samples from pigs, making safety and dosing tests very realistic.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Why test gene therapy in a CDKL5 large-animal model that shows spontaneous seizures?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Models that reproduce key human symptoms (for example spontaneous seizures) give much stronger evidence that a therapeutic effect is likely to translate. Rodents are essential for mechanism and screening, but some rodent models do not reliably reproduce spontaneous seizure phenotypes seen in patients; a large animal that can help resolve questions about dosing, distribution to relevant brain regions, and potential on-target/off-target effects in a brain more similar to humans. Because the blood‚Äìbrain barrier (BBB) and CSF flow can change with CDKL5 disorder, testing in a symptomatic large animal helps reveal issues that simple healthy-animal studies might miss.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>There have been recent adverse events in AAV clinical trials (e.g., the Capsida report). Does that affect our program?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Yes ‚Äî recent tragic events in other AAV trials underscore why robust, multi-species preclinical data and careful clinical design are essential. We monitor those cases closely (e.g., the recent Capsida trial report) to learn root-cause lessons and to update our safety plans, monitoring, and stopping rules accordingly. These events reinforce the need for careful dose selection, thorough biodistribution and toxicology, and independent safety oversight.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Why test CDKL5 gene therapy in a symptomatic large-animal model (like a pig with spontaneous seizures) instead of just rodents?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Rodents are useful for early research, but they don't show spontaneous seizures like CDKL5 patients and their brain physiology often differ from humans. Many mouse models of CDKL5 have engineered mutations or induced seizures that do not fully match the unpredictable, ongoing episodes seen in patients. Our large pig model naturally exhibits seizures similar to the human condition. Testing our therapy in this pig means treating a brain already in a diseased state. In this setting we can see whether the gene therapy reduces seizure frequency or causes any unexpected effects in a brain prone to seizures, which is closer to how the therapy would act in a child.</p>
                        <p>A diseased brain can also change how treatments spread. Seizures and neurodevelopmental disorders can alter the blood‚Äìbrain barrier (the brain's protective filter) and cerebrospinal fluid (CSF) flow. For example, repeated seizures can make the barrier more permeable. Because our pig's brain and CSF volume are similar to a human child's, we can measure exactly where and how much therapy enters the brain.</p>
                        <p>The recent Capsida trial tragedy (a patient death after an IV AAV gene therapy) underscores why this modeling matters. That trial required the vector to cross the blood‚Äìbrain barrier through the bloodstream, and investigators are still evaluating what happened. Our pig study lets us mimic similar delivery conditions in a controlled way. If ICM delivery triggers issues (such as excessive inflammation or organ stress), our pig data will reveal warning signs early. We can then adjust our approach (dose, delivery route, patient criteria) to avoid problems before moving to clinical trials.</p>
                        <p>A symptomatic large-animal model makes preclinical testing much closer to the human condition. It includes key disease features (like spontaneous seizures and altered brain barrier conditions), allowing us to spot and reduce risks early and design a safer, more effective therapy for patients.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Has our data been peer-reviewed or externally vetted by experts?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>Our research is still in preclinical stages, so it is still being worked on to be published. However, it is far from unexamined. We have a rigorous review process at every step. Internally, our scientific team analyzes and validates each finding. Externally, we collaborate with independent experts and regulators. For example, we have held pre-IND discussions with the FDA, where we presented our safety and efficacy data and received detailed feedback. We also consult with pediatric neurologists and rare-disease specialists who provide independent critique and guidance. In short, professionals with deep expertise evaluate our data long before we finalize any trial plans.</p>
                    </div>
                </div>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Are there safety concerns with AAV9, and how do we ensure safe use of this vector?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>AAV9 (and related AAV serotypes) has a substantial clinical track record but also known class risks that require careful management. The most prominent approved AAV9 therapy is ZOLGENSMA¬Æ for spinal muscular atrophy (SMA); thousands of patients have already received AAV9 under medical supervision. Its regulatory reviews and post-marketing experience document both benefit and recognized risks (e.g., transient liver enzyme elevations, thrombocytopenia, and immune responses), which are managed with monitoring and prophylactic measures. In short, AAV9's safety profile is well understood and largely favorable when proper precautions are taken. By applying those lessons ‚Äì choosing safe doses and delivery routes and conducting careful monitoring ‚Äì we plan to keep our CDKL5 gene therapy both effective and safe for patients.</p>
                    </div>
                </div>
            </div>
            
            <!-- Other -->
            <div class="faq-section" data-category="other">
                <h2 class="faq-section-title">üìã Other</h2>
                <div class="faq-accordion-item">
                    <button class="faq-accordion-question">
                        <span>Our baby is seen at Cleveland Clinic. Should she also be seen at Boston/Colorado?</span>
                        <span class="faq-accordion-arrow">‚ñº</span>
                    </button>
                    <div class="faq-accordion-answer">
                        <p>No, send a note to us through 'Contact Us' page on www.cdkl5genetherapy.com.</p>
                    </div>
                </div>
            </div>
        </div>
        
        <!-- No Results Message -->
        <div class="faq-no-results hidden">
            <p style="font-size: 1.2rem; margin-bottom: 0.5rem;">üòï No results found</p>
            <p>Try different keywords or browse all categories</p>
        </div>
        
        <!-- Contact CTA -->
        <div class="faq-contact-cta">
            <h3>Didn't find your answer?</h3>
            <p>We're here to help! Contact us for more information.</p>
            <a href="contact.html">Contact Us</a>
        </div>
    </main>
    
    <div data-include="inc/footer.html"></div>
    
    <script src="js/includes-loader.js"></script>
    <script>
        // FAQ Accordion Functionality
        document.addEventListener('DOMContentLoaded', function() {
            // Accordion toggle
            document.querySelectorAll('.faq-accordion-question').forEach(button => {
                button.addEventListener('click', function() {
                    const answer = this.nextElementSibling;
                    const isActive = this.classList.contains('active');
                    
                    // Close all others
                    document.querySelectorAll('.faq-accordion-question').forEach(btn => {
                        btn.classList.remove('active');
                        btn.nextElementSibling.classList.remove('active');
                    });
                    
                    // Toggle current
                    if (!isActive) {
                        this.classList.add('active');
                        answer.classList.add('active');
                    }
                });
            });
            
            // Category filter
            document.querySelectorAll('.faq-category-pill').forEach(pill => {
                pill.addEventListener('click', function() {
                    // Update active pill
                    document.querySelectorAll('.faq-category-pill').forEach(p => p.classList.remove('active'));
                    this.classList.add('active');
                    
                    const category = this.dataset.category;
                    const sections = document.querySelectorAll('.faq-section');
                    
                    if (category === 'all') {
                        sections.forEach(section => section.classList.remove('hidden'));
                    } else {
                        sections.forEach(section => {
                            if (section.dataset.category === category) {
                                section.classList.remove('hidden');
                            } else {
                                section.classList.add('hidden');
                            }
                        });
                    }
                    
                    // Reset search
                    document.getElementById('faqSearch').value = '';
                });
            });
            
            // Search functionality
            const searchInput = document.getElementById('faqSearch');
            searchInput.addEventListener('input', function() {
                const query = this.value.toLowerCase();
                const sections = document.querySelectorAll('.faq-section');
                const noResults = document.querySelector('.faq-no-results');
                let hasResults = false;
                
                // Reset category filter to "All" when searching
                if (query) {
                    document.querySelectorAll('.faq-category-pill').forEach(p => p.classList.remove('active'));
                    document.querySelector('[data-category="all"]').classList.add('active');
                }
                
                sections.forEach(section => {
                    const items = section.querySelectorAll('.faq-accordion-item');
                    let sectionHasResults = false;
                    
                    items.forEach(item => {
                        const question = item.querySelector('.faq-accordion-question span').textContent.toLowerCase();
                        const answer = item.querySelector('.faq-accordion-answer p').textContent.toLowerCase();
                        
                        if (question.includes(query) || answer.includes(query)) {
                            item.style.display = 'block';
                            sectionHasResults = true;
                            hasResults = true;
                        } else {
                            item.style.display = 'none';
                        }
                    });
                    
                    if (query) {
                        section.classList.toggle('hidden', !sectionHasResults);
                    } else {
                        section.classList.remove('hidden');
                        items.forEach(item => item.style.display = 'block');
                    }
                });
                
                noResults.classList.toggle('hidden', hasResults || !query);
            });
        });
    </script>
</body>
</html>
